Federated Hermes Inc. Has $28.15 Million Holdings in Vericel Corporation $VCEL

Federated Hermes Inc. decreased its holdings in shares of Vericel Corporation (NASDAQ:VCEL) by 21.9% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 894,608 shares of the biotechnology company’s stock after selling 250,651 shares during the period. Federated Hermes Inc.’s holdings in Vericel were worth $28,153,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Conestoga Capital Advisors LLC boosted its stake in Vericel by 19.5% in the second quarter. Conestoga Capital Advisors LLC now owns 2,463,590 shares of the biotechnology company’s stock valued at $104,826,000 after acquiring an additional 401,990 shares during the last quarter. Geneva Capital Management LLC lifted its stake in shares of Vericel by 30.7% in the 2nd quarter. Geneva Capital Management LLC now owns 1,784,927 shares of the biotechnology company’s stock valued at $75,949,000 after purchasing an additional 419,183 shares during the period. Geode Capital Management LLC lifted its stake in shares of Vericel by 3.2% in the 2nd quarter. Geode Capital Management LLC now owns 1,240,389 shares of the biotechnology company’s stock valued at $52,786,000 after purchasing an additional 38,799 shares during the period. Champlain Investment Partners LLC boosted its position in shares of Vericel by 62.5% in the 2nd quarter. Champlain Investment Partners LLC now owns 997,291 shares of the biotechnology company’s stock worth $42,435,000 after purchasing an additional 383,498 shares during the last quarter. Finally, New York State Common Retirement Fund grew its stake in shares of Vericel by 3.3% during the second quarter. New York State Common Retirement Fund now owns 890,509 shares of the biotechnology company’s stock worth $37,891,000 after purchasing an additional 28,178 shares during the period.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Zacks Research downgraded Vericel from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 12th. Wall Street Zen raised Vericel from a “hold” rating to a “buy” rating in a research note on Sunday, January 25th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Vericel in a research report on Monday, December 29th. Finally, Truist Financial decreased their price objective on shares of Vericel from $50.00 to $45.00 and set a “buy” rating for the company in a report on Thursday, December 18th. Four investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Vericel Stock Performance

Shares of VCEL stock opened at $35.98 on Friday. Vericel Corporation has a 52 week low of $29.24 and a 52 week high of $63.00. The company’s 50 day moving average price is $37.62 and its two-hundred day moving average price is $36.27. The company has a market capitalization of $1.82 billion, a P/E ratio of 149.92 and a beta of 1.17.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings data on Thursday, November 6th. The biotechnology company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.12. Vericel had a net margin of 5.06% and a return on equity of 4.30%. The company had revenue of $67.50 million during the quarter, compared to the consensus estimate of $64.57 million. During the same quarter in the prior year, the firm earned ($0.02) earnings per share. The firm’s revenue was up 16.6% compared to the same quarter last year. Analysts forecast that Vericel Corporation will post 0.14 earnings per share for the current year.

About Vericel

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.